Different angiogenic phenotypes in primary and secondary glioblastomas
The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Abstract
Primary and secondary glioblastomas (pGBM, sGBM) are supposed to evolve through different genetic pathways, including EGF receptor and PDGF and its receptor and thus genes that are involved in tumor‐induced angiogenesis. However, whether other angiogenic cytokines are also differentially expressed in these glioblastoma subtypes is not known so far, but this knowledge might be important to optimize an antiangiogenic therapy. Therefore, we studied the expression of several angiogenic cytokines, including VEGF‐A, HGF, bFGF, PDGF‐AB, PDGF‐BB, G‐CSF and GM‐CSF in pGBMs and sGBMs as well as in gliomas WHO III, the precursor lesions of sGBMs. In tumor tissues, expression of all cytokines was observed albeit with marked differences concerning intensity and distribution pattern. Quantification of the cytokines in the supernatant of 30 tissue‐corresponding glioma cultures revealed a predominant expression of VEGF‐A in pGBMs and significantly higher expression levels of PDGF‐AB in sGBMs. HGF and bFGF were determined in nearly all tumor cultures but with no GBM subtype or malignancy‐related differences. Interestingly, GM‐CSF and especially G‐CSF were produced less frequently by tumor cells. However, GM‐CSF secretion occurred together with an increased number of simultaneously secreted cytokines and correlated with a worse patient prognosis and may thus represent a more aggressive angiogenic phenotype. Finally, we confirmed an independent contribution of each tumor‐derived cytokine analyzed to tumor‐induced vascularization. Our data indicate that an optimal antiangiogenic therapy may require targeting of multiple angiogenic pathways that seem to differ markedly in pGBMs and sGBMs. © 2005 Wiley‐Liss, Inc.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Normalization of Tumor Vasculature: An Emerging Concept in Antiangiogenic Therapy
Jain, R. K. (2005) · Science · doi:10.1126/science.1104819 · Cited by 5,527
Cited by
Genetic Pathways to Primary and Secondary Glioblastoma
Ohgaki, H., & Kleihues, P. (2007) · The American Journal of Pathology · doi:10.2353/ajpath.2007.070011 · Cited by 1,497
The Definition of Primary and Secondary Glioblastoma
Ohgaki, H., & Kleihues, P. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-3002 · Cited by 1,132
Glioblastoma: pathology, molecular mechanisms and markers
Aldape, K., Zadeh, G., Mansouri, S., Reifenberger, G., & von Deimling, A. (2015) · Acta Neuropathologica · doi:10.1007/s00401-015-1432-1 · Cited by 735
Stem Cell Marker CD133 Affects Clinical Outcome in Glioma Patients
Zeppernick, F., Ahmadi, R., Campos, B., Dictus, C., Helmke, B. M., Becker, N., Lichter, P., Unterberg, A., Radlwimmer, B., & Herold-Mende, C. C. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-0932 · Cited by 588
Self-citationGlioblastoma multiforme: a review of where we have been and where we are going
Adamson, C., Kanu, O. O., Mehta, A. I., Di, C., Lin, N., Mattox, A. K., & Bigner, D. D. (2009) · Expert Opinion on Investigational Drugs · doi:10.1517/13543780903052764 · Cited by 550
Genetic alterations and signaling pathways in the evolution of gliomas
Ohgaki, H., & Kleihues, P. (2009) · Cancer Science · doi:10.1111/j.1349-7006.2009.01308.x · Cited by 355
Lohr, J., Ratliff, T., Huppertz, A., Ge, Y., Dictus, C., Ahmadi, R., Grau, S., Hiraoka, N., Eckstein, V., Ecker, R. C., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-2557 · Cited by 337
Self-citationDifferentiation Therapy Exerts Antitumor Effects on Stem-like Glioma Cells
Campos, B., Wan, F., Farhadi, M., Ernst, A., Zeppernick, F., Tagscherer, K. E., Ahmadi, R., Lohr, J., Dictus, C., Gdynia, G., et al. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-1800 · Cited by 313
Self-citationReview Glioblastoma multiforme – an overview
Urbańska, K., Sokołowska, J., Szmidt, M., & Sysa, P. (2014) · Współczesna Onkologia · doi:10.5114/wo.2014.40559 · Cited by 276
Molecular and Genomic Alterations in Glioblastoma Multiforme
Crespo, I., Vital, A. L., Gonzalez-Tablas, M., Patino, M. D. C., Otero, A., Lopes, M. C., de Oliveira, C., Domingues, P., Orfao, A., & Tabernero, M. D. (2015) · The American Journal of Pathology · doi:10.1016/j.ajpath.2015.02.023 · Cited by 225
Metadata
- Authors
- Karcher, S., Steiner, H., Ahmadi, R., Zoubaa, S., Vasvari, G., Bauer, H., Unterberg, A., & Herold‐Mende, C.
- Venue
- International Journal of Cancer
- Publisher
- Wiley
- Published
- 2005-12-05
- Volume
- 118
- Issue
- 9
- Pages
- 2182-2189
- ISSN
- 0020-7136 (ISSN-L)
- 1097-0215
- OpenAlex
- W1993427232
- Cited by
- 145
- References
- 1
- FWCI
- 2.77
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.